Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114594 · ClinicalTrials.gov registry record
Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
A clinical trial, sponsored by The Rogosin Institute.
- Completed
- Registry status
- 42
- Enrollment target
NCT01114594: Completed study, sponsored by The Rogosin Institute.
NCT01114594 is a clinical trial that has completed, run by The Rogosin Institute. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114594 has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
The aim of this pilot project is to assess the potential of urine micro-RNAs (miRNA) as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD) compared with patients with other causes of chronic kidney disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-04 |
What the finished NCT01114594 record still lists
NCT01114594 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01114594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01114594 about?
NCT01114594 is a clinical study titled "Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease". The aim of this pilot project is to assess the potential of urine micro-RNAs (miRNA) as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD) compared with patients with other causes of chronic kidney disease.
What is the current status of trial NCT01114594?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2010-04. Estimated completion is 2012-04.
Who is sponsoring clinical trial NCT01114594?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia